Covance’s Genomics Laboratory and the Institute for Systems Biology Collaborate to Further Research in Tumor Biology
|View printer-friendly version||<< Back|
PRINCETON, N.J., March 8, 2011 — Covance Inc. (NYSE: CVD) today announced that its Seattle-based genomics laboratory (www.covance.com/cgl) has initiated a collaboration with the Institute for Systems Biology (ISB) to further understand the area of brain tumor biology. Covance, a leading provider of genomics solutions for the drug discovery and development industry, and ISB, the leader in understanding complex biological systems, plan to work collectively to unravel the complex regulation of gene expression in Glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer.
This research project will bring together Covance’s expertise in genomics assays and ISB’s expertise in complex genomic networks. Having run more than 450,000 samples to date, Covance’s genomics laboratory provides end-to-end services for genomics-based development research and has demonstrated particular expertise in Next Generation Sequencing (NGS). NGS will be used to provide researchers an important dataset to investigate tumor heterogeneity and find targets for patient stratification and/or therapeutics. The goal of the collaboration is to enable research in brain tumor biology by providing a high-quality map of gene expression and RNA structure.
“We are delighted to be working with the ISB on this high value project, helping to empower research for this unmet medical need,” said Thomas Turi Ph.D., Vice President of Science and Technology for Covance Discovery and Translational Services. “By applying Covance’s expertise in genomics, guided by ISB’s expertise in analyzing integrated biological networks, we will gain a greater understanding of Glioblastoma multiforme.”
“Collaborating with Covance will help us better understand the disease of Glioblastoma multiforme biology” said Lee Hood M.D., Ph.D., President of the Institute for Systems Biology. “The ability to resolve complex regulatory networks requires reproducible, high-quality data. We know Covance’s experience in genomics and Next Generation Sequencing will give us an unprecedented level of high-quality data.”
Covance, with headquarters in
Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.